The trajectory of the erectile dysfunction drug presents a intricate picture for investors. While the initial release generated massive profits, the expiration of its patent opened the avenue to generic versions, https://wearethelist.com/story23826134/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity